Semin Respir Crit Care Med 2000; 21(5): 433-442
DOI: 10.1055/s-2000-9406
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Evidence-Based Outcomes for Patients with Non-Small Cell Lung Cancer Undergoing Resection

Valerie W. Rusch
  • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
Further Information

Publication History

Publication Date:
31 December 2000 (online)

ABSTRACT

Surgery plays a vital role in the management of Stages I-IIIa NSCLC. Careful patient selection and improved perioperative care now allow pulmonary resection to be performed with a very low morbidity and mortality even in older patients, or in patients undergoing pneumonectomy or extended operations. Most patients with Stage IIIb disease are not candidates for surgery, but resection can be curative for highly selected groups of patients with T4 tumors when these are not associated with nodal metastases. Surgery in conjunction with induction chemotherapy or chemoradiation has become a standard approach to the management of Stage IIIa (N2) disease and, in that setting, can be performed safely and effectively. The role of surgical resection in the treatment of NSCLC will undoubtedly continue to evolve as we gain a better understanding of the biology and multimodality therapy of this disease.

REFERENCES

  • 1 Ginsberg R J, Hill L D, Eagan R T. Modern thirty-day operative mortality for surgical resections in lung cancer.  J Thorac Cardiovasc Surg . 1983;  86 654-658
  • 2 Nagasaki F, Flehinger B J, Martini N. Complications of surgery in the treatment of carcinoma of the lung.  Chest . 1982;  82 25-29
  • 3 Wada H, Nakamura T, Nakamoto K, Maeda M, Watanabe Y. Thirty-day operative mortality for thoracotomy in lung cancer.  J Thorac Cardiovasc Surg . 1998;  115 70-73
  • 4 Pagni S, Federico J A, Ponn R B. Pulmonary resection for lung cancer in octogenarians.  Ann Thorac Surg . 1997;  63 785-789
  • 5 Grégoire J, Deslauriers J, Guojin L, Rouleau J. Indications, risks, and results of completion pneumonectomy.  J Thorac Cardiovasc Surg . 1993;  105 918-924
  • 6 Muysoms F E, de la Rivière B A, Defauw J J. Completion pneumonectomy: Analysis of operative mortality and survival.  Ann Thorac Surg . 1998;  66 1165-1169
  • 7 Deslauriers J, Ginsberg R J, Dubois P, Beaulieu M, Goldberg M, Piraux M. Current operative morbidity associated with elective surgical resection for lung cancer.  Can J Surg . 1989;  32 335-339
  • 8 Harpole Jr H D, Liptay M J, DeCamp Jr M M, Mentzer S J, Swanson S J, Sugarbaker D J. Prospective analysis of pneumonectomy: Risk factors for major morbidity and cardiac dysrhythmias.  Ann Thorac Surg . 1996;  61 977-982
  • 9 Duque J L, Ramos G, Castrodeza J. Early complications in surgical treatment of lung cancer: A prospective, multicenter study.  Ann Thorac Surg . 1997;  63 944-950
  • 10 Perez C A, Stanley K, Grundy G. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the Radiation Therapy Oncology Group.  Cancer . 1982;  50 1091-1099
  • 11 Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung.  Chest . 1995;  108 1278-1282
  • 12 Shields T W. The ``incomplete'' resection.  Ann Thorac Surg . 1989;  47 487-488
  • 13 Liewald F, Hatz R A, Dienemann H, Sunder-Plassmann L. Importance of microscopic residual disease at the bronchial margin after resection for non-small cell carcinoma of the lung.  J Thorac Cardiovasc Surg . 1992;  104 408-412
  • 14 Kaiser L R, Fleshner P, Keller S, Martini N. Significance of extramucosal residual tumor at the bronchial resection margin.  Ann Thorac Surg . 1989;  47 265-269
  • 15 Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system.  J Thorac Cardiovasc Surg . 1988;  96 440-447
  • 16 Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer.  J Thorac Cardiovasc Surg . 1978;  76 833-839
  • 17 Thomas P A, Piantadosi S, The Lung Cancer Study Group. Postoperative T1 N0 non-small cell lung cancer.  J Thorac Cardiovasc Surg . 1987;  94 349-354
  • 18 Gail M H, Eagan R T, Feld R. Prognostic factors in patients with resected stage I non- small cell lung cancer. A report from the Lung Cancer Study Group.  Cancer . 1984;  54 1802-1813
  • 19 Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small cell lung cancer. An analysis in each pathologic stage.  J Thorac Cardiovasc Surg . 1995;  110 601-605
  • 20 Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: Lobar or hilar nodes.  J Thorac Cardiovasc Surg . 1994;  107 1398-1402
  • 21 Martini N, Burt M E, Bains M S, McCormack P M, Rusch V W, Ginsberg R J. Survival after resection of stage II non-small cell lung cancer.  Ann Thorac Surg . 1992;  54 460-466
  • 22 Thomas P, Rubinstein L, The Lung Cancer Study Group. Cancer recurrence after resection: T1 N0 non-small cell lung cancer.  Ann Thorac Surg . 1990;  49 242-247
  • 23 The Ludwig Lung Cancer Study Group. Patterns of failure in patients with resected stage I and II non-small-cell carcinoma of the lung.  Ann Surg . 1987;  205 67-71
  • 24 Sorensen J B, Olsen J E. Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung.  J Thorac Cardiovasc Surg . 1989;  97 245-251
  • 25 Albain K S, Crowley J J, LeBlanc M, Livingston R B. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience.  J Clin Oncol . 1991;  9 1618-1626
  • 26 Mitsudomi T, Tateishi M, Oka T, Yano T, Ishida T, Sugimachi K. Longer survival after resection of non-small cell lung cancer in Japanese women.  Ann Thorac Surg . 1989;  48 639-642
  • 27 Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer.  Ann Thorac Surg . 1998;  65 1405-1409
  • 28 Bréchot J-M, Chevret S, Charpentier M-C. Blood vessel and lymphatic vesel invasion in resected non-small cell lung carcinoma. Correlation with TNM stage and disease free and overall survival.  Cancer . 1996;  78 2111-2118
  • 29 Kessler R, Gasser B, Massard G. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer.  Ann Thorac Surg . 1996;  62 1489-1493
  • 30 Izbicki J R, Passlick B, Hosch S B. Mode of spread in the early phase of lymphatic metastasis in non-small cell lung cancer: Significance of nodal micrometastasis.  J Thorac Cardiovasc Surg . 1996;  112 623-630
  • 31 Buhr J, Berghäuser K-H, Morr H, Dobroschke J, Ebner H J. Tumor cells in intraoperative pleural lavage. An indicator for the poor prognosis of bronchogenic carcinoma.  Cancer . 1990;  65 1801-1804
  • 32 Slebos R JC, Kibbelaar R E, Dalesio O. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.  N Engl J Med . 1990;  323 561-565
  • 33 Rodenhuis S, Slebos R JC. Clinical significance of ras oncogene activation in human lung cancer.  Cancer Res . 1992;  52 2665s-2669s
  • 34 Pastorino U, Andreola S, Tagliabue E. Immunocytochemical markers in Stage I lung cancer: Relevance to prognosis.  J Clin Oncol . 1997;  15 2858-2865
  • 35 Kwiatkowski D J, Harpole Jr H D, Godleski J. Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: Clinical implications.  J Clin Oncol . 1998;  16 2468-2477
  • 36 The Lung Cancer Study Group, Thomas Jr A P, Rubinstein L. Malignant disease appearing late after operation for T1 N0 non-small-cell lung cancer.  J Thorac Cardiovasc Surg . 1993;  106 1053-1058
  • 37 Yano T, Yokoyama H, Inoue T. The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. Comparison between pN0 disease and pN2 disease.  J Thorac Cardiovasc Surg . 1994;  108 680-683
  • 38 Jensik R J, Faber L P, Kittle C F, Meng R L. Survival following resection for second primary bronchogenic carcinoma.  J Thorac Cardiovasc Surg . 1981;  82 658-668
  • 39 Deschamps C, Pairolero P C, Trastek V F, Payne W S. Multiple primary lung cancers. Results of surgical treatment.  J Thorac Cardiovasc Surg . 1990;  99 769-778
  • 40 Martini N, Flehinger B J, Zaman M B, Beattie Jr J E. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases.  Ann Surg . 1983;  198 386-397
  • 41 Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. The prognosis of surgically resected N2 non-small cell lung cancer: The importance of clinical N status.  J Thorac Cardiovasc Surg . 1999;  118 145-153
  • 42 Patterson G A, Piazza D, Pearson F G. Significance of metastatic disease in subaortic lymph nodes.  Ann Thorac Surg . 1987;  43 155-159
  • 43 McCaughan B C, Martini N, Bains M S, McCormack P M. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications.  J Thorac Cardiovasc Surg . 1985;  89 836-841
  • 44 Downey R J, Martini N, Rusch V W, Bains M S, Korst R J, Ginsberg R J. Extent of chest wall invasion and survival in patients with lung cancer.  Ann Thorac Surg . 1999;  68 188-193
  • 45 Pitz C CM, de la Rivière B A, Elbers H RJ, Westermann C JJ, van den Bosch M M J. Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement.  Thorax . 1996;  51 846-850
  • 46 Pairolero P C, Arnold P G. Chest wall tumors. Experience with 100 consecutive patients.  J Thorac Cardiovasc Surg . 1985;  90 367-372
  • 47 Albertucci M, DeMeester T R, Rothberg M, Hagen J A, Santoscoy R, Smyrk T C. Surgery and the management of peripheral lung tumors adherent to the parietal pleura.  J Thorac Cardiovasc Surg . 1992;  103 8-13
  • 48 Spaggiari L, Rusca M, Carbognani P, Solli P. Hemivertebrectomy for apical chest tumors: Is risk justified by the outcome?.  Ann Thorac Surg . 1998;  65 1515-1517
  • 49 Pancoast H K, Henry K. Pancoast describes superior pulmonary sulcus tumor.  Surg Rounds . 1980;  January 29-32
  • 50 Shaw R R, Paulson D L, Kee Jr L J. Treatment of the superior sulcus tumor by irradiation followed by resection.  Ann Surg . 1961;  7 29-40
  • 51 Hagan M P, Choi N C, Mathisen D J, Wain J C, Wright C D, Grillo H C. Superior sulcus lung tumors: Impact of local control on survival.  J Thorac Cardiovasc Surg . 1999;  117 1086-1094
  • 52 Rusch V W, Parekh K R, Leon L. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus.  J Thorac Cardiovasc Surg . 2000;  119 1147-1153
  • 53 Paulson D L. Extended resection of bronchogenic carcinoma in the superior pulmonary sulcus.  Surgical Rounds . 1980;  January 10-21
  • 54 Dartevelle P G, Chapelier A R, Macchiarini P. Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet.  J Thorac Cardiovasc Surg . 1993;  105 1025-1034
  • 55 Spaggiari L, Pastorino U. Transmanubrial approach with antero-lateral thoracotomy for apical chest tumor.  Ann Thorac Surg . 1999;  68 590-593
  • 56 Bains M S, Ginsberg R J, Jones W G. The clamshell incision. An improved approach to bilateral pulmonary and mediastinal tumor.  Ann Thorac Surg . 1994;  58 30-33
  • 57 Martini N, Yellin A, Ginsberg R J. Management of non-small cell lung cancer with direct mediastinal involvement.  Ann Thorac Surg . 1994;  58 1447-1451
  • 58 Nakahashi H, Yasumoto K, Ishida T. Results of surgical treatment of patients with T3 non-small cell lung cancer.  Ann Thorac Surg . 1988;  46 178-181
  • 59 Pitz C CM, de la Rivière B A, Elbers H RJ, Westermann C JJ, van den Bosch M J. Results of resection of T3 non-small cell lung cancer invading the mediastinum or main bronchus.  Ann Thorac Surg . 1996;  62 1016-1020
  • 60 Weksler B, Bains M, Burt M. Resection of lung cancer invading the diaphragm.  J Thorac Cardiovasc Surg . 1997;  114 500-501
  • 61 Faber L P, Jensik R J, Kittle C F. Results of sleeve lobectomy for bronchogenic carcinoma in 101 patients.  Ann Thorac Surg . 1984;  37 279-285
  • 62 Mehran R J, Deslauriers J, Piraus M, Beaulieu M, Guimont C, Brisson J. Survival related to nodal status after sleeve resection for lung cancer.  J Thorac Cardiovasc Surg . 1994;  107 576-582
  • 63 Suen H-C, Meyers B F, Guthrie T. Favorable results after sleeve lobectomy or bronchoplasty for bronchial malignancies.  Ann Thorac Surg . 1999;  67 1557-1562
  • 64 Deslauriers J, Jacques L F. Sleeve pneumonectomy.  Chest Surg Clin North Am . 1995;  5 297-313
  • 65 Mitchell J D, Mathisen D J, Wright C D. Clinical experience with carinal resection.  J Thorac Cardiovasc Surg . 1999;  117 39-53
  • 66 Klepetko W, Wisser W, Birsan T. T4 lung tumors with infiltration of the thoracic aorta: Is an operation reasonable?.  Ann Thorac Surg . 1999;  67 340-344
  • 67 Rendina E A, Venuta F, De Giacomo T. Induction chemotherapy for T4 centrally located non-small cell lung cancer.  J Thorac Cardiovasc Surg . 1999;  117 225-233
  • 68 Albain K S, Rusch V W, Crowley J J. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group Phase II study 8805.  J Clin Oncol . 1995;  13 1880-1892
  • 69 Albain K, Rusch V, Crowley J. Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group study 8805.  Proc ASCO . 1999;  18 (Abstract) 467a
  • 70 Eberhardt W, Wilke H, Stamatis G. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: Mature results of a Phase II trial.  J Clin Oncol . 1998;  16 622-634
  • 71 The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected Stage II and Stage III epidermoid cancer of the lung.  N Engl J Med . 1986;  315 1377-1381
  • 72 Sawyer T E, Bonner J A, Gould P M. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carinoma with ipsilateral mediastinal lymph node involvement.  Cancer . 1997;  80 1399-1408
  • 73 Evans W K. Adjuvant chemotherapy: Results and perspectives.  Lung Cancer . 1995;  12(suppl 1) S35-S45
  • 74 Keller S M, Adak S, Wagner H. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIA non-small cell lung cancer: An intergroup trial (E3590).  Proc ASCO . 1999;  18 (Abstract) 465a
  • 75 Wada H, Hitomi S, Teramatsu T, The West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small cell lung cancer.  J Clin Oncol . 1996;  14 1048-1054
  • 76 Martini N, Kris M G, Flehinger B J. Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients.  Ann Thorac Surg . 1993;  55 1365-1374
  • 77 Rosell R, Gómez-Codina J, Camps C. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.  N Engl J Med . 1994;  330 153-158
  • 78 Roth J A, Fossella F, Komaki R. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.  J Nat Cancer Inst . 1994;  86 673-680
  • 79 Rusch V W, Albain K S, Crowley J J. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial.  J Thorac Cardiovasc Surg . 1993;  105 97-106
  • 80 Rusch V W, Albain K S, Crowley J J. Neoadjuvant therapy: A novel and effective treatment for stage IIIb non-small cell lung cancer.  Ann Thorac Surg . 1994;  58 290-2951
    >